Simultaneous Diffuse Sclerosis Variant of Papillary Thyroid Carcinoma and Diffuse Toxic Hyperplasia (Graves' Disease)

2004 ◽  
Vol 15 (1) ◽  
pp. 77-82 ◽  
Author(s):  
Gladell P. Paner ◽  
Jennifer L. Hunt ◽  
Marlyn C. Ciesla ◽  
Steven DeJong ◽  
Virginia LiVolsi
2019 ◽  
Vol 101 (5) ◽  
pp. e122-e124
Author(s):  
O Hamdy ◽  
S Raafat ◽  
GA Saleh ◽  
K Atallah ◽  
Mahmoud M Saleh ◽  
...  

Primary thyroid carcinoma after thyroid ablation by radioactive iodine is rare. We present a very rare condition of lateral apparent papillary thyroid carcinoma eight years after receiving radioactive iodine for thyrotoxicosis, which led to complete anatomical and functional involution of the thyroid gland.


2014 ◽  
Vol 226 (06/07) ◽  
pp. 379-381 ◽  
Author(s):  
J. Gesing ◽  
R. Pfaeffle ◽  
H. Christiansen ◽  
A. Keller ◽  
T. Lincke ◽  
...  

2019 ◽  
Author(s):  
Sara Lomelino Pinheiro ◽  
Tiago Silva ◽  
Conceicao Pereira ◽  
Valeriano Leite

2018 ◽  
Vol 91 (3) ◽  
pp. 210-215 ◽  
Author(s):  
Kazuhiro Shimura ◽  
Hironori Shibata ◽  
Yusuke Mizuno ◽  
Naoko Amano ◽  
Ken Hoshino ◽  
...  

Background: The risk factors for rapid growth and early metastasis of papillary thyroid carcinoma (PTC) and the role of coexisting Graves’ disease in the clinical course of PTC remain uncertain in children. Case Description: We report on a Japanese girl, whose PTC rapidly grew and metastasized within 4 years. Graves’ disease was diagnosed by the presence of serum TSH receptor antibodies at 8 years of age when thyroid ultrasonography detected no nodules. After 4 years of effective treatment with thiamazole, multifocal nodules – up to 47 mm in diameter – were detected on thyroid ultrasonography. Chest CT scan revealed multiple metastatic lesions in the lung. After total thyroidectomy, PTC was pathologically diagnosed. The patient underwent two courses of radioactive iodine (RAI) treatment, but the pulmonary metastatic lesions did not take up the RAI. Molecular analyses of the PTC tissue identified a TFG/NTRK1 chimeric gene and disclosed the preserved expression of TSHR and the reduced expression of SLC5A5 compared with non-tumor thyroid tissue. Conclusions: Rapid growth and early metastasis of PTC with coexisting Graves’ disease in this patient can be related to a combination of multiple factors including preserved TSHR expression, reduced SLC5A5 expression, and TFG/NTRK1 rearrangement.


2007 ◽  
Vol 122 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Y Erbil ◽  
U Barbaros ◽  
N Özbey ◽  
Y Kapran ◽  
M Tükenmez ◽  
...  

AbstractObjective:Thyroid nodules are frequently present in Graves' disease. The aim of this study was to evaluate the risk of thyroid carcinoma in Graves' disease patients, with and without ultrasonographically identified nodules, who subsequently underwent surgical treatment.Design:The study group included 150 consecutive patients with diagnosed Graves' disease who subsequently underwent surgery.Subjects:The patients were divided into two groups according to whether the pre-operative ultrasound scan showed diffuse parenchyma (group one; n = 70) or nodules (group two; n = 80).Results:Of the 150 patients, 18 (12 per cent) were found to have papillary thyroid carcinoma. Papillary carcinoma was found in seven patients (10 per cent) in group one and in 11 patients (1.7 per cent) in group two. After evaluating the overall groups, the incidence of carcinoma in the parenchyma outside a nodule was 67 per cent, whereas the incidence of carcinoma in a nodule was 33 per cent.Conclusion:Carcinoma can occur in Graves' disease patients without nodules, and the absence of nodules on ultrasonographic examination does not reduce the risk of malignancy.


Sign in / Sign up

Export Citation Format

Share Document